Formulation and radiochemical evaluation of a freeze-dried mixed peptide kit for the preparation of 68Ga-labeled peptides for PET imaging of somatostatin receptor positive neuroendocrine cancers

详细信息    查看全文

• 作者：Tapas Das (1)
  Mohini Bhadwal (1)
  H. D. Sarma (2)
  Sharmila Banerjee (1)
  
• 关键词：Somatostatin receptor imaging ; Peptide receptor scintigraphy ; Mixed peptide kit ; 68Ga ; DOTA ; TATE ; DOTA ; NOC ; Neuroendocrine cancers
• 刊名：Journal of Radioanalytical and Nuclear Chemistry
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：302
• 期：3
• 页码：1259-1264
• 全文大小：249 KB
• 参考文献：1. Kaltsas GA, Papadogias D, Makras P, Grossman AB (2005) Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr-Relat Cancer 12:683鈥?99 CrossRef
  2. Basu S, Kumar R, Rubello D, Fanti S, Alavi A (2008) PET imaging in neuroendocrine tumors: current status and future prospects. Minerva Endocrinol 33:257鈥?75
  3. Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J (2010) The role of ⁶⁸Ga-DOTA-TATE PET in patients with neuroendocrine tumors and negative or equivocal findings on ¹¹¹In-DTPA-Octreotide scintigraphy. J Nucl Med 51:875鈥?82 CrossRef
  4. Das T, Bhadwal M, Banerjee S, Sarma HD, Shinto A, Kamaleshwaran KK (2014) Preparation of DOTA-TATE and DOTA-NOC freeze-dried kits for formulation of patient doses of ¹⁷⁷Lu-labeled agents and their comparison for peptide receptor radionuclide therapy application. J Radioanal Nucl Chem 299:1389鈥?398 CrossRef
  5. Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester HJ, Culler M, Ginj M, Liu Q, Schonbrunn A, Reubi JC (2006) Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 47:502鈥?11
  6. Ambrosini V, Fant S (2014) ⁶⁸Ga-DOTA-peptides in the diagnosis of NET. PET Clin 9:37鈥?2 CrossRef
  7. Ambrosini V, Campana D, Tomassetti P, Fanti S (2012) ⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol Imaging 39:S52鈥揝60 CrossRef
  8. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, Maecke H (2007) Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labeled with other radiometals? Eur J Nucl Med Mol Imaging 34:982鈥?83 CrossRef
  9. Velikyan I (2014) Prospective of ⁶⁸Ga-Radiopharmaceutical development. Theranostics 4:47鈥?0 CrossRef
  10. Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME (2013) Comparison of ⁶⁸Ga-DOTA-NOC and ⁶⁸Ga-DOTA-TATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med 54:364鈥?72 CrossRef
  11. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Guggenberg EV, Bale R, Virgolini IJ (2007) ⁶⁸Ga-DOTA-Tyr³-Octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48:508鈥?18 CrossRef
  12. Breeman WAP, de Blois E, Chan HS, Konijnenberg M, Kwekkeboom DJ, Krenning EP (2011) ⁶⁸Ga-labeled DOTA-peptides and ⁶⁸Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med 41:314鈥?21 CrossRef
  13. de Herder WW, Hofland LJ, Lely AJV, Lamberts SWJ (2003) Somatostatin receptors in gastroenteropancreatic neuroendocrine tumours. Endocr-Relat Cancer 10:451鈥?58 CrossRef
  14. Guo RS, Shi PD, Zhou J, Chen YY (2013) Somatostatin receptors 3,4 and 5 play important roles in gall bladder cancer. Asian Pac J Cancer Prev 7:4071鈥?075 CrossRef
  15. Reubi JC, Waser B, Schaer JC, Laissue JA (2001) Somatostatin receptor sst1鈥搒st5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med Mol Imaging 28:836鈥?46 CrossRef
  16. Wehrmann C, Senftleben S, Zachert C, M眉ller D, Baum RP (2007) Results of individual patient dosimetry in peptide receptor radionuclide therapy with ¹⁷⁷Lu DOTA-TATE and ¹⁷⁷Lu DOTA-NOC. Cancer Biother Radiopharm 22:406鈥?16 CrossRef
  17. Ocak M, Demirci E, Kabasakal L, Aygun A, Tutar RO, Arman A, Kanmaz B (2013) Evaluation and comparison of ⁶⁸Ga-DOTA-TATE and ⁶⁸Ga-DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer. Nucl Med Commun 34:1084鈥?089 CrossRef
  18. Das T, Chakraborty S, Kallur KG, Venkatesh M, Banerjee S (2011) Preparation of patient doses of ¹⁷⁷Lu-DOTA-TATE using indigenously produced ¹⁷⁷Lu: the Indian experience. Cancer Biother Radiopharm 26:395鈥?00 CrossRef
  
• 作者单位：Tapas Das (1)
  Mohini Bhadwal (1)
  H. D. Sarma (2)
  Sharmila Banerjee (1)
  
  1. Radiopharmaceuticals Chemistry Section, Radiochemistry and Isotope Group, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India
  2. Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India
  
• ISSN：1588-2780

文摘

68Ga-labeled DOTA-coupled somatostatin analogue peptides are regularly being used for the PET imaging of patients suspected to be suffering from various types of neuroendocrine cancers over-expressing somatostatin receptors. The article describes the formulation of a freeze-dried mixed peptide kit containing equal amounts of DOTA-TATE and DOTA-NOC and the radiochemical evaluation of the kit for the easy and convenient preparation of 68Ga-labeled mixed radiopeptides. The simultaneous use of two different peptides in the kit is expected to perceive more cancerous lesions and may have a wider applicability in the diagnosis of neuroendocrine cancers.